首页 > 最新文献

Frontiers in Medicine最新文献

英文 中文
The role of digital health in respiratory diseases management: a narrative review of recent literature.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1361667
Malik A Althobiani, Anne-Marie Russell, Joseph Jacob, Yatharth Ranjan, Rami Ahmad, Amos A Folarin, John R Hurst, Joanna C Porter

This review provides a detailed overview of how digital health can be utilized in the management of Interstitial Lung Disease (ILD), and Chronic Obstructive Pulmonary Disease (COPD). ILD encompasses a diverse range of lung disorders characterized by inflammation and scarring of lung tissue, leading to restrictive lung physiology and impaired gas exchange, with symptoms including progressive dyspnoea, cough, and hypoxia. COPD which ranks as the third leading cause of death globally, is characterized by chronic lung inflammation causing irreversible airflow obstruction, recurrent exacerbations. While recent advances in digital health have shown promise, predicting disease progression in patients with ILD and exacerbation in patients with COPD remains challenging. This review explores the role of digital health in managing ILD and COPD, particularly focusing on telehealth and digital health technologies. Telehealth, defined broadly as the use of electronic information and telecommunications technologies in healthcare, has become increasingly relevant, especially during the COVID-19 pandemic. This review examines the role of digital health technologies in the management of ILD and COPD, with particular focus on telemedicine, and digital health tools. Remote monitoring technologies, including home spirometry and wearable devices, have demonstrated feasibility in managing respiratory diseases. However, challenges such as evidence, data reliability, varying adherence, education, and the high costs of data collection and lack of qualified clinicians present barriers for many national health systems.

{"title":"The role of digital health in respiratory diseases management: a narrative review of recent literature.","authors":"Malik A Althobiani, Anne-Marie Russell, Joseph Jacob, Yatharth Ranjan, Rami Ahmad, Amos A Folarin, John R Hurst, Joanna C Porter","doi":"10.3389/fmed.2025.1361667","DOIUrl":"10.3389/fmed.2025.1361667","url":null,"abstract":"<p><p>This review provides a detailed overview of how digital health can be utilized in the management of Interstitial Lung Disease (ILD), and Chronic Obstructive Pulmonary Disease (COPD). ILD encompasses a diverse range of lung disorders characterized by inflammation and scarring of lung tissue, leading to restrictive lung physiology and impaired gas exchange, with symptoms including progressive dyspnoea, cough, and hypoxia. COPD which ranks as the third leading cause of death globally, is characterized by chronic lung inflammation causing irreversible airflow obstruction, recurrent exacerbations. While recent advances in digital health have shown promise, predicting disease progression in patients with ILD and exacerbation in patients with COPD remains challenging. This review explores the role of digital health in managing ILD and COPD, particularly focusing on telehealth and digital health technologies. Telehealth, defined broadly as the use of electronic information and telecommunications technologies in healthcare, has become increasingly relevant, especially during the COVID-19 pandemic. This review examines the role of digital health technologies in the management of ILD and COPD, with particular focus on telemedicine, and digital health tools. Remote monitoring technologies, including home spirometry and wearable devices, have demonstrated feasibility in managing respiratory diseases. However, challenges such as evidence, data reliability, varying adherence, education, and the high costs of data collection and lack of qualified clinicians present barriers for many national health systems.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1361667"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Visual performance, light distortion and patient reported outcomes with a new bi-aspheric non-diffractive extended depth of focus intraocular lens.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1513803
Santiago Tañá-Sanz, Pedro Tañá-Sanz, Belén Elvira-Giner, Paz Orts-Vila, Pedro Tañá-Rivero

Background: To evaluate refractive, visual, and patient-reported outcomes three months after bilateral implantation of a novel bi-aspheric, non-diffractive extended depth of focus (EDOF) intraocular lens (IOL) using PhaseRing technology to achieve good vision across distances with reduced dysphotopsia.

Methods: Twenty-two patients received bilateral Asqelio EDOF IOLs (AST VisionCare Inc.) and were evaluated 3 months post-surgery. The main outcomes assessed were refractive error, monocular and binocular visual acuities at distance, intermediate (67 cm) and near (40 cm), low contrast visual acuity, defocus curves, contrast sensitivity, and patient questionnaires.

Results: The average postoperative spherical equivalent was -0.31 ± 0.30 D. Astigmatism of ≤ 1.00 D was present in all eyes (100%, n = 44), with 75% (n = 33) showing astigmatism of ≤ 0.50 D. Every patient attained a corrected distance visual acuity (CDVA) of 20/25 or better and a distance-corrected intermediate visual acuity (DCIVA) of 20/32 or better. Contrast sensitivity met or exceeded normal levels under both photopic and mesopic conditions, with and without glare, except at 12 cycles per degree under mesopic conditions with glare. Light distortion index was comparable to published reports on monofocal IOLs and other non-diffractive EDOF IOLs, and lower than diffractive multifocal IOLs. Post-surgery, 90.9% (n = 20) of patients reported being satisfied with their vision. No significant visual symptoms were reported.

Conclusion: Asqelio™ EDOF IOL offers an efficient design, providing good clinical outcomes for distance and intermediate vision, while some patients reach functional levels of near vision. Its non-diffractive design minimizes dysphotopsia and reduces light distortion compared to other presbyopia-correcting IOLs.

{"title":"Visual performance, light distortion and patient reported outcomes with a new bi-aspheric non-diffractive extended depth of focus intraocular lens.","authors":"Santiago Tañá-Sanz, Pedro Tañá-Sanz, Belén Elvira-Giner, Paz Orts-Vila, Pedro Tañá-Rivero","doi":"10.3389/fmed.2025.1513803","DOIUrl":"10.3389/fmed.2025.1513803","url":null,"abstract":"<p><strong>Background: </strong>To evaluate refractive, visual, and patient-reported outcomes three months after bilateral implantation of a novel bi-aspheric, non-diffractive extended depth of focus (EDOF) intraocular lens (IOL) using PhaseRing technology to achieve good vision across distances with reduced dysphotopsia.</p><p><strong>Methods: </strong>Twenty-two patients received bilateral Asqelio EDOF IOLs (AST VisionCare Inc.) and were evaluated 3 months post-surgery. The main outcomes assessed were refractive error, monocular and binocular visual acuities at distance, intermediate (67 cm) and near (40 cm), low contrast visual acuity, defocus curves, contrast sensitivity, and patient questionnaires.</p><p><strong>Results: </strong>The average postoperative spherical equivalent was -0.31 ± 0.30 D. Astigmatism of ≤ 1.00 D was present in all eyes (100%, <i>n</i> = 44), with 75% (<i>n</i> = 33) showing astigmatism of ≤ 0.50 D. Every patient attained a corrected distance visual acuity (CDVA) of 20/25 or better and a distance-corrected intermediate visual acuity (DCIVA) of 20/32 or better. Contrast sensitivity met or exceeded normal levels under both photopic and mesopic conditions, with and without glare, except at 12 cycles per degree under mesopic conditions with glare. Light distortion index was comparable to published reports on monofocal IOLs and other non-diffractive EDOF IOLs, and lower than diffractive multifocal IOLs. Post-surgery, 90.9% (<i>n</i> = 20) of patients reported being satisfied with their vision. No significant visual symptoms were reported.</p><p><strong>Conclusion: </strong>Asqelio™ EDOF IOL offers an efficient design, providing good clinical outcomes for distance and intermediate vision, while some patients reach functional levels of near vision. Its non-diffractive design minimizes dysphotopsia and reduces light distortion compared to other presbyopia-correcting IOLs.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1513803"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11900891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of physical activity on all-cause mortality in individuals with non-cystic fibrosis bronchiectasis.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1479638
Sang Hyuk Kim, Hayoung Choi, Kyungdo Han, Jin-Hyung Jung, Bumhee Yang, Hyun Lee

Background: Little information is available regarding whether active physical activity lowers mortality risk in individuals with bronchiectasis.

Methods: We used the Korean National Health Insurance Service database from 2010 to 2016 to evaluate the association between changes in physical activity and mortality risk in individuals with bronchiectasis. Of 552,510 individuals with newly diagnosed bronchiectasis, we enrolled 165,842 individuals who had two consecutive health examinations before and after bronchiectasis diagnosis, within two years, as the study aimed to measure changes in exercise habits between the two time points. Active physical activity was defined as engaging in moderate- or vigorous-intensity physical activity at least once a week, either before or after bronchiectasis diagnosis. The outcome measure was all-cause mortality.

Results: During a mean follow-up of 6.2 ± 2.1 years, 10,535 (6.4%) individuals with bronchiectasis died. Individuals with bronchiectasis who were physically active exhibited a lower mortality rate than those who were physically inactive. Mortality reduction was particularly evident in the exercise maintainers group (aHR [adjusted hazard ratio] = 0.69, 95% confidence interval [CI] = 0.64-0.74) and individuals with physical activity ≥1,000 metabolic equivalent of task-min per week (aHR = 0.73, 95% CI = 0.70-0.77) compared to those who were physically inactive.

Conclusion: Engaging in active physical activity is associated with a decreased risk of mortality in individuals with bronchiectasis.

{"title":"Impact of physical activity on all-cause mortality in individuals with non-cystic fibrosis bronchiectasis.","authors":"Sang Hyuk Kim, Hayoung Choi, Kyungdo Han, Jin-Hyung Jung, Bumhee Yang, Hyun Lee","doi":"10.3389/fmed.2025.1479638","DOIUrl":"10.3389/fmed.2025.1479638","url":null,"abstract":"<p><strong>Background: </strong>Little information is available regarding whether active physical activity lowers mortality risk in individuals with bronchiectasis.</p><p><strong>Methods: </strong>We used the Korean National Health Insurance Service database from 2010 to 2016 to evaluate the association between changes in physical activity and mortality risk in individuals with bronchiectasis. Of 552,510 individuals with newly diagnosed bronchiectasis, we enrolled 165,842 individuals who had two consecutive health examinations before and after bronchiectasis diagnosis, within two years, as the study aimed to measure changes in exercise habits between the two time points. Active physical activity was defined as engaging in moderate- or vigorous-intensity physical activity at least once a week, either before or after bronchiectasis diagnosis. The outcome measure was all-cause mortality.</p><p><strong>Results: </strong>During a mean follow-up of 6.2 ± 2.1 years, 10,535 (6.4%) individuals with bronchiectasis died. Individuals with bronchiectasis who were physically active exhibited a lower mortality rate than those who were physically inactive. Mortality reduction was particularly evident in the exercise maintainers group (aHR [adjusted hazard ratio] = 0.69, 95% confidence interval [CI] = 0.64-0.74) and individuals with physical activity ≥1,000 metabolic equivalent of task-min per week (aHR = 0.73, 95% CI = 0.70-0.77) compared to those who were physically inactive.</p><p><strong>Conclusion: </strong>Engaging in active physical activity is associated with a decreased risk of mortality in individuals with bronchiectasis.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1479638"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of c-MET in oesophageal squamous cell carcinoma: a study based on the mRNA expression in TCGA database and a meta-analysis.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1548160
Qiqi Zhang, Xiujuan Li, Jian Li, Zhiqiang Zhang

Objective: This study aims to assess the mesenchymal-epithelial transition factor's (c-MET) prognostic value in oesophageal carcinoma (ESCA) through a meta-analysis and bioinformatics.

Methods: We analysed c-MET expression in ESCA tissues using data from The Cancer Genome Atlas (TCGA) and conducted a meta-analysis to evaluate its association with clinicopathological factors and survival outcomes. The meta-analysis included studies reporting hazard ratios (HRs) and odds ratios (ORs) for survival and metastatic outcomes.

Results: The Cancer Genome Atlas analysis revealed elevated c-MET expression in ESCA, which was significantly correlated with lymph node metastasis, tumour grade and stage, though not with overall survival (OS). In the meta-analysis, 278 publications were identified, and 89 duplicates were removed. After screening, 176 articles were excluded, leaving 13 for full-text review. Of these, 5 studies lacked sufficient survival data, resulting in 8 eligible studies with a total of 1,488 patients. Meta-analysis findings indicated that high c-MET expression was associated with worse OS (HR = 1.54, 95% confidence interval [CI]: 1.17-2.01; p = 0.002), distant metastasis (OR = 1.97, 95% CI: 1.14-3.40; p = 0.02) and advanced stage (OR = 2.23, 95% CI: 1.41-3.53; p = 0.0006).

Conclusion: High c-MET expression is associated with poor prognosis and advanced disease in ESCA, highlighting its potential as a biomarker for risk stratification. Further studies are needed to confirm its prognostic value and explore therapeutic implications.

{"title":"Prognostic value of c-MET in oesophageal squamous cell carcinoma: a study based on the mRNA expression in TCGA database and a meta-analysis.","authors":"Qiqi Zhang, Xiujuan Li, Jian Li, Zhiqiang Zhang","doi":"10.3389/fmed.2025.1548160","DOIUrl":"10.3389/fmed.2025.1548160","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to assess the mesenchymal-epithelial transition factor's (c-MET) prognostic value in oesophageal carcinoma (ESCA) through a meta-analysis and bioinformatics.</p><p><strong>Methods: </strong>We analysed c-MET expression in ESCA tissues using data from The Cancer Genome Atlas (TCGA) and conducted a meta-analysis to evaluate its association with clinicopathological factors and survival outcomes. The meta-analysis included studies reporting hazard ratios (HRs) and odds ratios (ORs) for survival and metastatic outcomes.</p><p><strong>Results: </strong>The Cancer Genome Atlas analysis revealed elevated c-MET expression in ESCA, which was significantly correlated with lymph node metastasis, tumour grade and stage, though not with overall survival (OS). In the meta-analysis, 278 publications were identified, and 89 duplicates were removed. After screening, 176 articles were excluded, leaving 13 for full-text review. Of these, 5 studies lacked sufficient survival data, resulting in 8 eligible studies with a total of 1,488 patients. Meta-analysis findings indicated that high c-MET expression was associated with worse OS (HR = 1.54, 95% confidence interval [CI]: 1.17-2.01; <i>p</i> = 0.002), distant metastasis (OR = 1.97, 95% CI: 1.14-3.40; <i>p</i> = 0.02) and advanced stage (OR = 2.23, 95% CI: 1.41-3.53; <i>p</i> = 0.0006).</p><p><strong>Conclusion: </strong>High c-MET expression is associated with poor prognosis and advanced disease in ESCA, highlighting its potential as a biomarker for risk stratification. Further studies are needed to confirm its prognostic value and explore therapeutic implications.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1548160"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design and validation of a cross-cultural virtual exchange experience among bilingual medical students.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1339277
John R Vaile, Cierrah Doran, Arlene R Maheu, Valentina Jaramillo, Daniela A Perez-Chadid, Tomas Fernandez, Carissa C Walkosak, Dinah Roll Velez, Sara Carolina Bedoya Osorio, Courtney Seebadri-White, Susan Truong, Dimitrios Papanagnou, Andres Fernandez, Rosemary Frasso

Exposure to cross-cultural medical education is essential for professionals aiming to work in global health or serve diverse communities. However, traditional in-person exchange programs can be complex, costly, and restricted, particularly during times when travel is limited, such as during the COVID-19 pandemic. These challenges prompted us to explore novel approaches to support cross-cultural exchange programs. We designed, piloted, and evaluated a cross-cultural virtual exchange experience using case-based learning (CBL). Our study involved 14 bilingual medical students from the United States and Colombia who participated in four virtual CBL sessions. Following each session, participants engaged in guided discussions to reflect on their attitudes toward the experience, and content analysis was framed by sociocultural learning theory (SCLT). This study provides justification and operational guidance for implementing and improving upon cross-cultural virtual exchange experiences among medical trainees, with potential applicability to other contexts.

{"title":"Design and validation of a cross-cultural virtual exchange experience among bilingual medical students.","authors":"John R Vaile, Cierrah Doran, Arlene R Maheu, Valentina Jaramillo, Daniela A Perez-Chadid, Tomas Fernandez, Carissa C Walkosak, Dinah Roll Velez, Sara Carolina Bedoya Osorio, Courtney Seebadri-White, Susan Truong, Dimitrios Papanagnou, Andres Fernandez, Rosemary Frasso","doi":"10.3389/fmed.2025.1339277","DOIUrl":"10.3389/fmed.2025.1339277","url":null,"abstract":"<p><p>Exposure to cross-cultural medical education is essential for professionals aiming to work in global health or serve diverse communities. However, traditional in-person exchange programs can be complex, costly, and restricted, particularly during times when travel is limited, such as during the COVID-19 pandemic. These challenges prompted us to explore novel approaches to support cross-cultural exchange programs. We designed, piloted, and evaluated a cross-cultural virtual exchange experience using case-based learning (CBL). Our study involved 14 bilingual medical students from the United States and Colombia who participated in four virtual CBL sessions. Following each session, participants engaged in guided discussions to reflect on their attitudes toward the experience, and content analysis was framed by sociocultural learning theory (SCLT). This study provides justification and operational guidance for implementing and improving upon cross-cultural virtual exchange experiences among medical trainees, with potential applicability to other contexts.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1339277"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Choroidal metastases from thoracic cancer: a retrospective study on clinical characteristics and treatment efficacy.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1491278
Xiacheng Lin, Yusheng Zhong, Haiping Li, Yating Yang, Ahui Liu, Yajing Shi, Jianhong Liang, Yong Cheng

Objective: This study aimed to examine the clinical characteristics of choroidal metastases (CMs) and assess the efficacy of various treatment strategies for CMs in a specific patient cohort.

Methods: This retrospective case series study included 32 patients (38 eyes) diagnosed with CM at the Department of Ophthalmology, Peking University People's Hospital, between 2009 and 2022. The cohort included 10 male patients (10 eyes) and 22 female patients (28 eyes), with a mean age of 52.53 ± 10.81 years. Detailed medical histories and multiple ophthalmic examinations were performed for all patients, with diagnoses confirmed by two senior ophthalmologists. Clinical characteristics, treatment responses, and follow-up outcomes were analyzed.

Results: Lung cancer was the most common primary tumor (53.1%), with six patients initially presenting with ocular symptoms. Initial ultrasound imaging revealed a mean tumor height of 3.02 mm and a mean basal diameter of 11.09 mm. Optical coherence tomography (OCT) revealed irregular, highly reflective foci with undulating anterior surfaces, and fluorescein angiography (FFA) revealed early choroidal tumor masking and late-phase mottled hyperfluorescence with occasional leakage. Indocyanine green angiography (ICGA) revealed hypofluorescence in early and late phases, with slightly mottled hyperfluorescence in the late phase. The follow-up period ranged from 3 months to 4 years (median 4 months), during which systemic and local treatments effectively controlled or delayed tumor progression in most patients.

Conclusion: Lung and breast cancers are the leading sources of CMs, with bilateral or multifocal lesions more frequently linked to breast cancer. Treatment for CMs should be meticulously individualized and should take into account the patient's overall condition, tumor burden, and precise tumor location. Local treatment is essential for patients with significant ocular symptoms. A combination of local and systemic treatments has been shown to lead to a more significant reduction in tumor burden.

{"title":"Choroidal metastases from thoracic cancer: a retrospective study on clinical characteristics and treatment efficacy.","authors":"Xiacheng Lin, Yusheng Zhong, Haiping Li, Yating Yang, Ahui Liu, Yajing Shi, Jianhong Liang, Yong Cheng","doi":"10.3389/fmed.2025.1491278","DOIUrl":"10.3389/fmed.2025.1491278","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to examine the clinical characteristics of choroidal metastases (CMs) and assess the efficacy of various treatment strategies for CMs in a specific patient cohort.</p><p><strong>Methods: </strong>This retrospective case series study included 32 patients (38 eyes) diagnosed with CM at the Department of Ophthalmology, Peking University People's Hospital, between 2009 and 2022. The cohort included 10 male patients (10 eyes) and 22 female patients (28 eyes), with a mean age of 52.53 ± 10.81 years. Detailed medical histories and multiple ophthalmic examinations were performed for all patients, with diagnoses confirmed by two senior ophthalmologists. Clinical characteristics, treatment responses, and follow-up outcomes were analyzed.</p><p><strong>Results: </strong>Lung cancer was the most common primary tumor (53.1%), with six patients initially presenting with ocular symptoms. Initial ultrasound imaging revealed a mean tumor height of 3.02 mm and a mean basal diameter of 11.09 mm. Optical coherence tomography (OCT) revealed irregular, highly reflective foci with undulating anterior surfaces, and fluorescein angiography (FFA) revealed early choroidal tumor masking and late-phase mottled hyperfluorescence with occasional leakage. Indocyanine green angiography (ICGA) revealed hypofluorescence in early and late phases, with slightly mottled hyperfluorescence in the late phase. The follow-up period ranged from 3 months to 4 years (median 4 months), during which systemic and local treatments effectively controlled or delayed tumor progression in most patients.</p><p><strong>Conclusion: </strong>Lung and breast cancers are the leading sources of CMs, with bilateral or multifocal lesions more frequently linked to breast cancer. Treatment for CMs should be meticulously individualized and should take into account the patient's overall condition, tumor burden, and precise tumor location. Local treatment is essential for patients with significant ocular symptoms. A combination of local and systemic treatments has been shown to lead to a more significant reduction in tumor burden.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1491278"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Advances in cutaneous microbial infections.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1573853
Fuqiu Li, Liyan Xi, Sihong Song
{"title":"Editorial: Advances in cutaneous microbial infections.","authors":"Fuqiu Li, Liyan Xi, Sihong Song","doi":"10.3389/fmed.2025.1573853","DOIUrl":"https://doi.org/10.3389/fmed.2025.1573853","url":null,"abstract":"","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1573853"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Superselective superior rectal artery embolization in the treatment of hemorrhoidal disease.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1530981
Tao Jiang, Lichao Fan, Xuesong Tang, Zhigang Xu, Wenjiang Wu

Hemorrhoids are a prevalent and benign anal disorder for which minimally invasive treatments are increasingly preferred. The UK National Institute for Health and Care Excellence clinical guideline (2010) recommends hemorrhoidal artery ligation as a treatment option for hemorrhoidal disease. Superior rectal artery embolization (SRAE) leverages this principle by using digital subtraction angiography to precisely identify and superselectively embolize the arteries supplying the hemorrhoidal region. This procedure has demonstrated favorable clinical outcomes. SRAE is minimally invasive, painless, preserves the anal sphincter and normal anal anatomy, and offers a quick recovery, establishing it as an effective minimally invasive surgical option. As a result, this technique has gained increasing clinical recognition and adoption. This article examines the efficacy and safety of superselective SRAE for hemorrhoidal disease.

{"title":"Superselective superior rectal artery embolization in the treatment of hemorrhoidal disease.","authors":"Tao Jiang, Lichao Fan, Xuesong Tang, Zhigang Xu, Wenjiang Wu","doi":"10.3389/fmed.2025.1530981","DOIUrl":"10.3389/fmed.2025.1530981","url":null,"abstract":"<p><p>Hemorrhoids are a prevalent and benign anal disorder for which minimally invasive treatments are increasingly preferred. The UK National Institute for Health and Care Excellence clinical guideline (2010) recommends hemorrhoidal artery ligation as a treatment option for hemorrhoidal disease. Superior rectal artery embolization (SRAE) leverages this principle by using digital subtraction angiography to precisely identify and superselectively embolize the arteries supplying the hemorrhoidal region. This procedure has demonstrated favorable clinical outcomes. SRAE is minimally invasive, painless, preserves the anal sphincter and normal anal anatomy, and offers a quick recovery, establishing it as an effective minimally invasive surgical option. As a result, this technique has gained increasing clinical recognition and adoption. This article examines the efficacy and safety of superselective SRAE for hemorrhoidal disease.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1530981"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Upfront fixed-duration treatment strategies for chronic lymphocytic leukemia in Arab populations: a position statement from the Gulf region.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1509074
Mohamed A Yassin, Khalil Al Farsi, Anas Hamad, Rola Ghasoub, Ahmad Alhuraiji, Kayane Mheidly, Hasan Aal Yaseen, Hani Osman, Martin Trepel

The treatment landscape for chronic lymphocytic leukemia (CLL) has expanded dramatically over the last decade, with a wide range of effective treatments now available. Clinical management of CLL varies widely depending on patient profile, meaning the optimal treatment in Arab patients, who tend to be young and often present with comorbidities, including diabetes and obesity, requires specific considerations. In the absence of regional guidelines, a group of experts from across the Gulf region and one international expert from Germany convened to discuss and agree upon a position statement for venetoclax-based fixed-duration treatment strategies for Arab patients with CLL. Our position is that ibrutinib-venetoclax should be the first choice as first-line therapy for all fit CLL patients in the region, regardless of age. The advantages of an all-oral, fixed-duration treatment are discussed in the context of a young Arab patient population, including excellent patient and physician convenience, limited accumulative risk of toxicities, uncomplicated logistics, and low burden of healthcare administration costs. Finally, we discuss the management of key safety considerations in Arab populations including ethnic neutropenia, risk of cardiotoxic events, considerations during intermittent fasting, and avoiding adverse drug-drug interactions, e.g., with anti-tuberculosis or anti-obesity medications.

{"title":"Upfront fixed-duration treatment strategies for chronic lymphocytic leukemia in Arab populations: a position statement from the Gulf region.","authors":"Mohamed A Yassin, Khalil Al Farsi, Anas Hamad, Rola Ghasoub, Ahmad Alhuraiji, Kayane Mheidly, Hasan Aal Yaseen, Hani Osman, Martin Trepel","doi":"10.3389/fmed.2025.1509074","DOIUrl":"10.3389/fmed.2025.1509074","url":null,"abstract":"<p><p>The treatment landscape for chronic lymphocytic leukemia (CLL) has expanded dramatically over the last decade, with a wide range of effective treatments now available. Clinical management of CLL varies widely depending on patient profile, meaning the optimal treatment in Arab patients, who tend to be young and often present with comorbidities, including diabetes and obesity, requires specific considerations. In the absence of regional guidelines, a group of experts from across the Gulf region and one international expert from Germany convened to discuss and agree upon a position statement for venetoclax-based fixed-duration treatment strategies for Arab patients with CLL. Our position is that ibrutinib-venetoclax should be the first choice as first-line therapy for all fit CLL patients in the region, regardless of age. The advantages of an all-oral, fixed-duration treatment are discussed in the context of a young Arab patient population, including excellent patient and physician convenience, limited accumulative risk of toxicities, uncomplicated logistics, and low burden of healthcare administration costs. Finally, we discuss the management of key safety considerations in Arab populations including ethnic neutropenia, risk of cardiotoxic events, considerations during intermittent fasting, and avoiding adverse drug-drug interactions, e.g., with anti-tuberculosis or anti-obesity medications.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1509074"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Micro-encapsulated and colonic-release sodium butyrate modulates gut microbiota and improves abdominal pain in patients with symptomatic uncomplicated diverticular disease.
IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.3389/fmed.2025.1487892
Antonio Tursi, Giorgia Procaccianti, Rudi De Bastiani, Silvia Turroni, Federica D'Amico, Leonardo Allegretta, Natale Antonino, Elisabetta Baldi, Carlo Casamassima, Giovanni Casella, Mario Ciuffi, Marco De Bastiani, Lorenzo Lazzarotto, Claudio Licci, Maurizio Mancuso, Antonio Penna, Giuseppe Pranzo, Guido Sanna, Cesare Tosetti, Maria Zamparella, Marcello Picchio

The role of gut microbiota (GM) in the pathogenesis of Symptomatic Uncomplicated Diverticular Disease (SUDD) remains controversial. Here, we assessed the efficacy of a butyrate formulation in modulating GM and abdominal pain in patients with SUDD. A retrospective study was conducted in patients with SUDD who were treated with a delayed- and colonic-release formulation of butyrate (two capsules bid, for a total dose of 400 mg butyrate) for 3 months. GM was profiled before (T0) and after 90 days of treatment (T2) using 16S rRNA amplicon sequencing. The primary endpoint was change in GM at T2; secondary endpoints were reduction in abdominal pain severity according to VAS (Visual Analog Scale, 0: absence; 10: maximum severity) at T1 (45 days) and T2, stool characteristics according to the Bristol stool form scale at T0, T1 and T2, and safety of treatment. Fifty-nine patients with SUDD (59.3% male; median age 65.5 years, interquartile range 55-71 years) completed treatment. The butyrate formulation increased GM diversity and resulted in several compositional changes that were closely related to baseline abdominal pain severity. Regarding secondary endpoints, abdominal pain decreased significantly over time, while the Bristol stool form scale did not. Mild adverse events were recorded in 3 (5.08%) patients. This study showed that a microencapsulated and colonic-release formulation of butyrate favorably modulates GM and reduces abdominal pain in patients with SUDD.

{"title":"Micro-encapsulated and colonic-release sodium butyrate modulates gut microbiota and improves abdominal pain in patients with symptomatic uncomplicated diverticular disease.","authors":"Antonio Tursi, Giorgia Procaccianti, Rudi De Bastiani, Silvia Turroni, Federica D'Amico, Leonardo Allegretta, Natale Antonino, Elisabetta Baldi, Carlo Casamassima, Giovanni Casella, Mario Ciuffi, Marco De Bastiani, Lorenzo Lazzarotto, Claudio Licci, Maurizio Mancuso, Antonio Penna, Giuseppe Pranzo, Guido Sanna, Cesare Tosetti, Maria Zamparella, Marcello Picchio","doi":"10.3389/fmed.2025.1487892","DOIUrl":"10.3389/fmed.2025.1487892","url":null,"abstract":"<p><p>The role of gut microbiota (GM) in the pathogenesis of Symptomatic Uncomplicated Diverticular Disease (SUDD) remains controversial. Here, we assessed the efficacy of a butyrate formulation in modulating GM and abdominal pain in patients with SUDD. A retrospective study was conducted in patients with SUDD who were treated with a delayed- and colonic-release formulation of butyrate (two capsules bid, for a total dose of 400 mg butyrate) for 3 months. GM was profiled before (T0) and after 90 days of treatment (T2) using 16S rRNA amplicon sequencing. The primary endpoint was change in GM at T2; secondary endpoints were reduction in abdominal pain severity according to VAS (Visual Analog Scale, 0: absence; 10: maximum severity) at T1 (45 days) and T2, stool characteristics according to the Bristol stool form scale at T0, T1 and T2, and safety of treatment. Fifty-nine patients with SUDD (59.3% male; median age 65.5 years, interquartile range 55-71 years) completed treatment. The butyrate formulation increased GM diversity and resulted in several compositional changes that were closely related to baseline abdominal pain severity. Regarding secondary endpoints, abdominal pain decreased significantly over time, while the Bristol stool form scale did not. Mild adverse events were recorded in 3 (5.08%) patients. This study showed that a microencapsulated and colonic-release formulation of butyrate favorably modulates GM and reduces abdominal pain in patients with SUDD.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1487892"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1